Abstract B42: Patient stratification and precision medicine in pancreatic cancer: GemciTest, an innovative in vitro diagnostic for the decision-making process of pancreatic cancer treatment

Abstract

Abstract Pancreatic cancer is currently the 4th leading cause of death by cancer in Europe. If no action is taken, it is set to be 2nd by 2021. For nearly 80% of patients, diagnosis occurs at an advanced stage, too late (metastatic pancreatic adenocarcinoma; mPDAC), making them nonelective for surgery. The high mortality rate (less than 5% of patients alive at 5 years), is partly due to the difficulty to diagnose and to the lack of patients’ stratification for effective treatments. Despite advances in treatment and outcomes, the capability of biomarkers to improve treatment is potentially greater than in any other area of current medical research. Based on a multicenter, randomized, retrospective clinical phase III evaluation (ClinicalTrials.gov: NCT00789633), Acobiom identified an 11-gene blood signature and developed the GemciTest, an IVD associated with gemcitabine treatment in mPDAC. This blood signature evaluates both progression-free survival (PFS) and overall survival (OS) rates, and identifies the patients who are likely to benefit from 1st-line gemcitabine treatment. Briefly, the IVD allows to identify 37% of patients having a median overall survival of 15 months with 1-year survival rate superior to 65%. The GemciTest, a quantitative real-time PCR assay, is currently a prototype in an operational environment through a Clinician Peer Network in EU and US. In this context, Acobiom is always looking for new partnerships (public or private), the right way to open opportunities to develop the GemciTest solution for mPDAC patients (bench-to-bedside), and to assist physicians in routine patient care. Citation Format: Didier Ritter, David Piquemal, Florian Noguier, Fabien Pierrat, Roman Bruno. Patient stratification and precision medicine in pancreatic cancer: GemciTest, an innovative in vitro diagnostic for the decision-making process of pancreatic cancer treatment [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care; 2019 Sept 6-9; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2019;79(24 Suppl):Abstract nr B42.